ExCulture is a company founded in 2019 headquartered in the Netherlands. Its most recent tracked round is Seed. Brouky records 1 investor associated with the company.
ExCulture specializes in fermentation bioprocess technology to develop an animal-free substitute for heparin, a critical blood thinner, using a mixed-culture fermentation process.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.